Skip to main content

Featured

Weekly Market Snapshot: Records Everywhere as a Blowout Canadian Jobs Report Meets a Shock U.S. Loss

  August 8, 2026 A short, holiday-shortened week still managed to deliver record after record. The TSX, the S&P 500, the Nasdaq, and Europe's major indices all closed the week at or near all-time highs — even as Friday's jobs numbers told two very different stories on either side of the border. Here's everything that moved your money this week, and what to watch next. The Bottom Line The TSX capped its biggest weekly advance in about four months, closing Friday at a record 36,381.23 after Canada added a blowout 75,100 jobs in July (versus 17,800 expected). Wall Street also hit fresh records — but for the opposite reason: US employers unexpectedly cut 23,000 jobs, which markets read as reducing the odds of any further Fed rate hikes. Add in a fourth straight record close for European stocks, a wild swing in oil, and gold pushing toward US$4,400/oz, and it was a week where almost every major asset class ended up higher. 🇨🇦 Canada: TSX's Best Week Since April Canadia...
Post a Comment
Read more

article

Labels

Quebec Declines Coverage for Newly Approved Alzheimer’s Treatment

 

Quebec has announced that it will not cover the cost of lecanemab (Leqembi®), the first disease-modifying Alzheimer’s drug recently approved by Health Canada. The medication, conditionally approved in late October 2025, is designed to slow the progression of early-stage Alzheimer’s disease by targeting amyloid plaques in the brain.

Health Canada’s approval was hailed as a breakthrough, offering hope to patients and families grappling with the devastating effects of dementia. Lecanemab has shown the ability to reduce cognitive decline by about 27% over 18 months in clinical trials. Despite this, Quebec’s public drug insurance plan, administered by the Régie de l’assurance maladie du Québec (RAMQ), has confirmed that the treatment will not be added to its list of covered medications.

The decision raises concerns about accessibility and affordability, as the drug is expected to be costly. While other provinces may still evaluate whether to include lecanemab in their formularies, Quebec’s refusal highlights ongoing debates about the balance between innovation, cost-effectiveness, and equitable access to care.

Advocates, including the Alzheimer Society of Canada, argue that denying coverage could leave many patients without access to a therapy that represents the first real step toward slowing the disease’s progression. Families and healthcare professionals are now calling for further discussions on how Canada’s healthcare system can adapt to emerging treatments that may reshape the future of dementia care.


Labels:

Comments

Post a Comment